Healthcare Organizations Call for FDA Action on Compounding Regulations Amid GLP-1 Shortages
March 23, 2025 - 10:21
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) have taken a significant step by sending a letter to the U.S. Food and Drug Administration (FDA). This letter, supported by over 20 prominent organizations and providers from various sectors of healthcare, emphasizes the urgent need for the FDA to implement and enforce federal regulations concerning compounding practices.
The call to action comes in the wake of recent shortages of GLP-1 medications, which are crucial for the treatment of obesity and related conditions. These shortages have raised serious concerns about patient access to essential therapies. The coalition argues that without stricter oversight and regulation of compounded medications, patients may face continued disruptions in their treatment options.
Healthcare leaders are advocating for a timely response from the FDA to ensure that patients receive the medications they need without interruption, highlighting the importance of regulatory frameworks in safeguarding public health.
MORE NEWS
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...
July 21, 2026 - 06:41
The rise of Zyn-like pouches for sleep, health, focus, teethThe success of Zyn nicotine pouches has sparked a wave of copycat products that promise to deliver everything from better sleep to sharper focus, all through a small pouch tucked inside the lip....
July 20, 2026 - 19:14
FDA says it’s still investigating Taylor Farms in cyclosporiasis outbreakThe U.S. Food and Drug Administration has clarified that a false-positive lab result does not alter the `overwhelming epidemiological data` pointing to Taylor Farms as the source of a...
July 20, 2026 - 11:31
Seven peptides are under review by an FDA panel this week. Here’s everything we knowA federal advisory committee is set to meet this week to evaluate seven peptide products, a move that could reshape how these compounds are made and prescribed in the United States. The panel,...